SLE and Other Connective Tissue Disease Presentations in Hospitalized Children

Overview: Severe Multisystem Disease in Pediatric SLE and CTD

Children with systemic lupus erythematosus (SLE) often experience a more aggressive disease course than adults, with higher rates of major organ involvement—especially kidneys and the central nervous system—and increased morbidity. Pediatric SLE (pSLE), which accounts for approximately 10–20% of all SLE cases, is a relatively rare but severe autoimmune disease capable of affecting nearly any organ system. No organ is spared in this multisystem disease—children may present with symptoms ranging from rashes and arthritis to life-threatening renal, neurologic, pulmonary, or cardiac involvement. Early diagnosis can be challenging due to the heterogeneous presentation; however, prompt recognition is essential to prevent adverse outcomes. Hospitalized pediatric patients with SLE or other inflammatory connective tissue diseases (CTDs) often experience severe flares or complications, such as organ failure, thrombotic microangiopathy, or overwhelming infection. Other pediatric CTDs (e.g., juvenile dermatomyositis, systemic sclerosis, mixed or undifferentiated CTD) can also present with acute, organ-threatening manifestations requiring inpatient management. Below, we outline major organ system presentations of SLE/CTD flares in hospitalized children, along with special complications like TTP and infection considerations.

Major Organ Involvement Requiring Hospitalization

Kidney (Lupus Nephritis): Renal involvement is one of the most common serious manifestations of pSLE. Approximately 50–60% of children with SLE develop lupus nephritis, often early in the disease course. Children may present with nephrotic-range proteinuria, hematuria, hypertension, and acute kidney injury. Severe cases (e.g., Class III/IV nephritis) can lead to rapidly progressive glomerulonephritis, fluid overload, or uremia, requiring hospitalization for aggressive immunosuppressive therapy and renal support. Kidney involvement significantly contributes to SLE morbidity and mortality—renal failure and nephritis are among the leading causes of death in pediatric SLE. Early detection through urinalysis (for protein or blood) and renal function tests, along with prompt treatment (high-dose corticosteroids, cyclophosphamide, or mycophenolate), is crucial to prevent permanent damage.

Central Nervous System (CNS): Neuropsychiatric SLE occurs in approximately 20–30% of children and can be a serious cause of hospitalization. Children may present with seizures, acute confusional state, stroke, severe headaches, psychosis, or other neurological deficits. Stroke or transient ischemic attacks may result from vasculitis or antiphospholipid syndrome, while seizures or encephalopathy can indicate acute CNS inflammation. A UK cohort found that about 25% of juvenile-onset SLE patients experienced neuropsychiatric involvement within 5 years, including headaches, mood changes, cognitive impairment, anxiety, seizures, and even cerebrovascular disease. Any child with SLE presenting with altered mental status, focal deficits, or persistent severe headache warrants urgent evaluation, including neuroimaging, lumbar puncture if safe, and EEG. Management often involves high-dose steroids and immunosuppressants; if cerebral vasculitis or catastrophic antiphospholipid syndrome is suspected, additional therapies (e.g., plasma exchange, anticoagulation) may be necessary. Close monitoring in an ICU setting may be required for severe cases (e.g., status epilepticus or CNS hemorrhage).

Pulmonary Involvement: Pulmonary complications of SLE, although less common than renal or CNS issues, can be life-threatening. Pleurisy with effusions is relatively common during lupus flares (some series report pleuritic chest pain or effusions in up to approximately 50–60% of pediatric cases). While uncomfortable, it usually responds well to therapy. More dangerous are lupus pneumonitis or Diffuse Alveolar Hemorrhage (DAH). DAH is fortunately rare (estimated in only about 1–5% of SLE patients) but has a very high mortality rate (over 50% in many reports). It typically presents acutely with dyspnea, tachypnea, cough, hemoptysis (coughing up blood), rapidly falling hemoglobin levels, and new diffuse lung infiltrates on imaging. DAH often occurs in patients with known SLE (usually within a few years of diagnosis), but it can sometimes be the first sign of lupus. Pediatric SLE patients seem to have an even higher mortality rate from DAH than adults. Any suspected alveolar hemorrhage requires ICU admission for respiratory support (including mechanical ventilation) and aggressive treatment, such as high-dose corticosteroids, cyclophosphamide or other cytotoxic agents, plasmapheresis, and so on. Other lupus-related lung issues include pulmonary embolism (especially if antiphospholipid antibodies are present) and shrinking lung syndrome (progressive diaphragmatic dysfunction causing restrictive lung disease, which is rare in acute cases). In other connective tissue diseases, conditions such as juvenile dermatomyositis can lead to interstitial lung disease and hypoxemic respiratory failure. At the same time, systemic sclerosis can lead to pulmonary hypertension or ILD, both of which may need inpatient care and specialized therapies.

Cardiac and Vascular: SLE can affect the heart and blood vessels in several ways. Pericarditis is common during lupus flares, often presenting as chest pain and pericardial effusion seen on echo, and large effusions can cause cardiac tamponade requiring urgent intervention. Myocarditis due to lupus is less common but may present with arrhythmias, heart failure, or cardiogenic shock. Lupus can also lead to Libman-Sacks endocarditis, which involves sterile vegetations on valves; while it rarely causes acute symptoms, it can embolize. Coronary vasculitis or early atherosclerosis, caused by chronic inflammation and steroid use, can result in myocardial infarction even in young patients. Although acute MI in pediatric lupus patients is rare, it has been reported as a cause of death in young adults. Vasculitis affecting medium or small vessels can occur in SLE and other connective tissue diseases, sometimes causing skin ulcers or systemic ischemia. A particularly severe vascular complication is catastrophic antiphospholipid syndrome (CAPS) in individuals with antiphospholipid antibodies, leading to widespread microthromboses and multi-organ failure, often requiring ICU care. Any child with lupus presenting with acute chest pain, arrhythmia, or signs of poor perfusion should undergo prompt evaluation with an echocardiogram and ECG. Pericardial effusions causing hemodynamic instability require urgent drainage. High-dose steroids are indicated for myocarditis or severe pericarditis, and immunosuppressants like IV cyclophosphamide may be used for severe cardiac lupus.

Gastrointestinal (GI): GI manifestations of connective tissue diseases (CTDs) can resemble surgical emergencies. Lupus may cause mesenteric vasculitis, resulting in severe abdominal pain, bowel wall thickening visible on imaging, and increased risk of bowel ischemia or perforation. These cases often require hospitalization to differentiate from conditions like appendicitis or other causes of acute abdomen; treatment typically involves immunosuppression rather than surgery, unless complications such as perforation develop. Children with active systemic lupus erythematosus (SLE) may also develop pancreatitis (sometimes linked to steroid use or vasculitis), hepatitis (lupus hepatitis or medication-induced), or serositis, which can cause abdominal pain (peritoneal serositis). Gastrointestinal bleeding may occur from mucosal ulcerations or steroid-induced gastritis. In juvenile dermatomyositis, an inflammatory CTD affecting muscles, GI involvement can include intestinal perforation due to chronic corticosteroid use or vasculopathy in the gut. Always consider abdominal imaging (ultrasound or CT) in children with CTD and severe abdominal pain, and involve both rheumatology and surgery teams early to manage these complex scenarios.

Hematologic Manifestations: Cytopenias are common in SLE and related CTDs. Many children have Coombs-positive hemolytic anemia, leukopenia, or thrombocytopenia as part of their disease. Mild to moderate cytopenias can often be managed outpatient, but severe hematologic flares may require hospitalization for transfusions or urgent therapy. For example, a child with lupus might present with profound anemia (due to hemolysis or bone marrow suppression), causing syncope or high-output cardiac failure, or with platelets <20k leading to bleeding. High-dose corticosteroids (and sometimes IV immunoglobulin) are used for severe autoimmune hemolysis or thrombocytopenia. Another life-threatening hematologic complication is Macrophage Activation Syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis. MAS can complicate various rheumatic diseases (most often systemic JIA, but also SLE). It is an overwhelming inflammatory reaction characterized by persistent high fevers, cytopenias, liver dysfunction, coagulopathy, neurologic symptoms, and extremely high ferritin levels. Although not very frequent in pediatric SLE, MAS is likely under-recognized and can be triggered by active disease or infections. Its onset is often acute and can overlap with features of severe lupus flare or sepsis, making diagnosis challenging. MAS is highly lethal if untreated; therapy involves aggressive immunosuppression (high-dose steroids, cyclosporine, biologics like anakinra, or etoposide per HLH protocols) and supportive ICU care. Any child with CTD who experiences unremitting fever, falling blood counts, and organ failure should be evaluated for MAS (with laboratory tests such as ferritin, fibrinogen, triglycerides, and soluble IL-2 receptor) even as infections are being treated.

Thrombotic Thrombocytopenic Purpura (TTP) in SLE and CTDs

Thrombotic thrombocytopenic purpura is a rare but serious complication that can occur in SLE (and occasionally other CTDs) as a form of thrombotic microangiopathy. Studies estimate TTP occurs in about 1–4% of SLE patients. It is characterized by the classic pentad (or triad) of microangiopathic hemolytic anemia (MAHA), severe thrombocytopenia, and organ ischemia (often involving the brain and kidneys), sometimes with fever and neurological symptoms. In TTP, microscopic clots form in small vessels due to a severe deficiency of the ADAMTS13 enzyme (often from autoantibodies), leading to uncontrolled platelet aggregation. SLE patients are predisposed to TTP because autoantibodies and endothelial injury in lupus can trigger ADAMTS13 dysfunction and platelet-vWF clumping.

In the context of SLE, TTP often presents with a sudden onset and rapid progression, rendering it a medical emergency. A child with lupus-associated TTP (sometimes called TMA in SLE) might present with unexplained seizures or altered mental status (due to cerebral ischemia), acute renal failure, high LDH levels with schistocytes on blood smear, and very low platelet counts (despite surprisingly little bleeding, given the thrombocytopenia). Differentiating an SLE flare with severe cytopenias from superimposed TTP can be challenging. Features favoring TTP include evidence of MAHA (schistocytes, elevated LDH, low haptoglobin) that is disproportionate to lupus activity, along with very low ADAMTS13 levels (although these results may take time). Clinically, it may be indistinguishable from other causes of thrombotic microangiopathy, such as atypical HUS or disseminated intravascular coagulation (DIC); additionally, active lupus itself can sometimes produce a TMA-like appearance even without classic TTP. Because true TTP is often fatal if not treated promptly, a high index of suspicion is essential. Early recognition and treatment are crucial. Therapy for TTP in SLE typically involves plasma exchange (plasmapheresis) as the primary intervention, which removes autoantibodies and replenishes ADAMTS13, in combination with high-dose corticosteroids and often rituximab or other immunosuppressants. In refractory cases or severe presentations, newer therapies such as caplacizumab (an anti-von Willebrand factor nanobody) have been successfully used in pediatric TTP-SLE to halt microthrombi formation rapidly. Supportive care for organ damage—such as dialysis for renal failure and ICU monitoring for neurological symptoms—is also vital. Risk factors for developing TTP in lupus include very high disease activity, renal involvement, and certain metabolic factors. Notably, short-term mortality in SLE-associated TTP remains high; one recent adult study highlighted that this condition is life-threatening, underscoring the need for prompt, aggressive treatment. In summary, any hospitalized lupus patient with hemolytic anemia and thrombocytopenia should be considered for TTP. Initiating plasma exchange early—even before confirmatory ADAMTS13 results—can be lifesaving.

Infectious Complications in Hospitalized CTD Patients

Infection is a significant concern in any hospitalized pediatric rheumatology patient. Infections are among the leading causes of death in childhood-onset SLE. Several factors contribute to this increased susceptibility. First, SLE and related connective tissue diseases (CTDs) inherently involve immune dysregulation – for example, complement defects or functional asplenia caused by autoantibody-mediated cell destruction – which can weaken normal immune defenses. Second, the treatments used to manage the disease (such as corticosteroids, cyclophosphamide, mycophenolate, biologics, and others) are immunosuppressive, thereby increasing the risk of opportunistic infections. In one cohort of Indian children with lupus, 26% experienced infections, and more than half of those were considered serious; notably, the presence of serious infection significantly predicted mortality. Most deaths in pediatric SLE are due to infection (often sepsis or pneumonia) or active organ damage, such as renal failure or CNS involvement.

Common infections: Hospitalized CTD patients can contract the same infections as any immunocompromised host. Bacterial infections, such as pneumonia (e.g., Streptococcus pneumoniae), urinary tract infections, or sepsis from gram-negative organisms, are common, especially in patients who are on high-dose steroids or have leukopenia. Viral infections can also be severe; herpes zoster (shingles) may disseminate in a child on immunosuppression, and community viruses like influenza or RSV can cause intense illness. Opportunistic infections are a particular concern for those on prolonged immunosuppressive therapy. Although not very frequent in pediatrics, Pneumocystis jirovecii pneumonia (PCP) has been reported as a serious complication of childhood SLE—it should be considered if a child on steroids or cytotoxics develops subacute fever, cough, and hypoxia. Fungal infections (such as invasive candidiasis or aspergillosis) and tuberculosis (especially in regions where TB is prevalent or if the child received biologics) are other examples of opportunistic infections. Many centers will place children with lupus on Pneumocystis prophylaxis (e.g., trimethoprim-sulfamethoxazole thrice weekly) when they are on high-dose corticosteroids or cyclophosphamide, reflecting the need to prevent opportunistic infections.

Diagnostic challenge – flare vs. infection: A key issue for inpatient providers is distinguishing an autoimmune flare (active CTD inflammation) from an infection, or recognizing when they occur together. Both conditions can present with fever, elevated inflammatory markers, fatigue, rash, or organ dysfunction. For example, lupus itself can cause fever and a high C-reactive protein, and even sterile pleurisy can resemble pneumonia on imaging. Conversely, an unrecognized infection (such as occult bacterial sepsis or fungal pneumonia) can be mistakenly attributed to “active lupus” if one is not careful. This overlap means that in a deteriorating CTD patient, providers must evaluate for infection while also managing a potential flare. Practical steps include obtaining cultures (blood, urine, sputum) and starting broad-spectrum antibiotics early in a febrile immunosuppressed patient, even as immunosuppressive therapy for a flare is intensified. Specific tests can sometimes be helpful: for instance, procalcitonin levels might be higher in bacterial infections than in lupus flares (though not perfect), and extremely high IL-2 receptor levels might indicate MAS rather than a simple infection. Consulting rheumatology early is recommended—they can assess disease activity (e.g., trending complement levels, anti-dsDNA titers) and determine if pulse steroids or other treatments are needed. In contrast, infectious disease specialists guide the workup for hidden infections. Often, a collaborative approach is necessary: treat for both possibilities until the diagnosis becomes clear.

Infection control and prophylaxis: In the hospital, children with active CTDs should be managed with infection prevention in mind. Ensure that immunizations are current (although live vaccines are contraindicated during immunosuppression, so preventing exposures is essential). Use prophylactic antibiotics when appropriate, such as PCP prophylaxis, acyclovir prophylaxis for individuals with a history of herpes, and antifungal prophylaxis for those with neutropenia. Monitor closely for hospital-acquired infections — invasive devices, such as central lines, Foley catheters, and ventilators, increase the risk, so remove them as soon as feasible. Educate families that minor infections can escalate quickly in these patients; a fever at home in a child with lupus on immunosuppressants should prompt immediate medical evaluation.

In summary, infections pose a significant challenge in managing hospitalized patients with CTD. A high index of suspicion, aggressive diagnostic workup, and early treatment of infections (without waiting too long for confirmation) are essential in any immunosuppressed rheumatologic patient who deteriorates. Balancing immunosuppression to control the disease while protecting the child from infection is an ongoing tightrope that inpatient providers must navigate.

Conclusion

Hospitalized pediatric patients with SLE or related connective tissue diseases often require a multidisciplinary, high-acuity approach due to the potential for severe organ involvement, life-threatening complications like TTP or MAS, and increased risk of infections. Key principles include early recognition of organ-threatening conditions (e.g., nephritis, neuropsychiatric lupus, alveolar hemorrhage), prompt initiation of appropriate immunosuppressive therapy (often before a definitive diagnosis is confirmed, as in suspected TTP), and vigilant monitoring for infections in any deteriorating patient. Outcomes for pediatric SLE have improved significantly over recent decades (5-year survival now >90%), but mortality remains largely driven by active disease and infections. Therefore, first-line providers (hospitalists, intensivists, general pediatricians) must be prepared to identify these complex scenarios and coordinate care with pediatric rheumatologists. With timely intervention and collaborative efforts, even the most severe manifestations—such as kidney failure, CNS lupus, TTP, or MAS—can often be successfully managed. The main goal is to control autoimmune inflammation while supporting failing organs and preventing complications, thereby giving the child the best chance at recovery and long-term health despite these serious rheumatic diseases.

Sources:

• Levy DM & Kamphuis S. Systemic Lupus Erythematosus in Children and Adolescents. Pediatr Clin North Am. 2012;59(2):345-364. [Key points about cSLE severity]
  
• Aggarwal A, et al. Outcomes in juvenile onset lupus: single center cohort. Lupus. 2018;27(11):1867-75. [Organ involvement stats and infection outcomes]
  
• Medscape – Petty RE, et al. Pediatric Systemic Lupus Erythematosus. (2023 update) [Multisystem involvement, causes of mortality]
  
• Ma H, et al. Features and risk factors of TTP in SLE. Orphanet J Rare Dis. 2025;20:203. [TTP prevalence, characteristics in SLE]
  
• Yokoyama T, et al. TTP with juvenile SLE – case report. Pediatr Rheumatol. 2024;22:106. [Pediatric TTP-SLE management insights]
  
• Abdirakhmanova A, et al. MAS in pediatric SLE: diagnostic review. Front Med (Lausanne). 2021;8:621558. [MAS is severe, life-threatening in pSLE]
  
• Kasap-Demir B, et al. Diffuse alveolar hemorrhage in juvenile SLE – case-based review. Mediterr J Rheumatol. 2022;33(1):124-129. [DAH incidence and mortality in jSLE]